Organon stock presents new VTAMA analysis ahead of November results
Organon stock (OGN) is gaining investor attention with new real-world analysis of its VTAMA cream for atopic dermatitis, presented ahead of its November earnings report. Despite a 2.3% revenue decline in Q2 2026, the company's stock is trading near its 52-week high, valued at $13.72 as of October 2, 2026. This positive product development and a recent regulatory milestone for its MIUDELLA intrauterine device are central to the company's current narrative, focusing on women's health and specialty medicines, despite analyst targets remaining below the current stock price.
Organon presents VTAMA analysis: Organon stock gains 1.16 percent
Organon stock saw a 1.16 percent gain after the company announced it would present new real-world data for its VTAMA cream at the 2026 Fall Clinical Dermatology Conference. The analysis focuses on VTAMA's effectiveness in patients with atopic dermatitis, evaluating physician-reported outcomes and patient itch scores, complementing existing clinical trial data. Despite the stock gain, analyst consensus remains cautious with a "Reduce" rating and an average price target below the current market quote.
One of the first large-scale real-world analyses of an eczema cream will be shown
Organon (NYSE: OGN) announced it will present new real-world analysis of its VTAMA (tapinarof) cream, 1% for atopic dermatitis at the 2026 Fall Clinical Dermatology Conference. This analysis will be one of the first large-scale real-world effectiveness studies of VTAMA cream in patients with atopic dermatitis, evaluating improvements in physician-reported and patient-reported outcomes. VTAMA cream is an aryl hydrocarbon receptor (AhR) agonist indicated for the topical treatment of plaque psoriasis and atopic dermatitis in adults and pediatric patients aged 2 years and older.
Tangible book value per share of Organon & Co. – HAN:7XP
This article provides the tangible book value per share for Organon & Co. (HAN:7XP) on the Hannover Stock Exchange. The current market status is closed with no trades recorded. The data is presented within the context of financial overview for the company.
Organon & Co. Revenue Breakdown – HAN:7XP
Organon & Co. generated 5.29 billion EUR in revenue last year. The "Established Brands" segment was the top-performing, contributing 3.14 billion EUR. Geographically, Europe and Canada were the largest contributors, accounting for 1.38 billion EUR.
Sun Pharma Plans Rs 10,000 Crore Rupee Debt Sale To Refinance Organon Deal: Report
Sun Pharmaceutical Industries is reportedly planning to raise around Rs 10,000 crore through a rupee-denominated debt sale. This move is intended to partly refinance a bridge loan taken for its acquisition of US healthcare company Organon & Co. The fundraising involves bonds with maturities of two, three, and four years, as Indian companies increasingly look to the domestic debt market due to higher global borrowing costs.
Organon Backs Women’s Health Efforts Across India
Organon announced two grants in India to support women's health, focusing on adolescent health in Bihar and expanding contraceptive access in Uttar Pradesh. These initiatives, in partnership with Population Services International India and Ipas Development Foundation, address different stages of a woman's life, from education to reproductive choices. The effort follows Sun Pharmaceutical Industries' acquisition of Organon, highlighting a significant investment in women's health in India.
how InvestingPro spotted Organon’s 65% gain in healthcare sector By Investing.com
InvestingPro accurately predicted Organon & Co.'s significant stock surge, identifying it as an undervalued pharmaceutical company in early 2026. Despite an initial downturn, InvestingPro's Fair Value analysis highlighted strong fundamentals and an intrinsic value well above its trading price. This insight led to a 64.63% return for the stock, validated by catalysts like acquisition bids and pipeline advancements.
Sun Pharma gets ratings boost from Moody's, S&P over $11.75 bn Organon & Co acquisition bid
Rating agencies Moody's and S&P have assigned investment-grade ratings to Sun Pharmaceutical Industries following its proposed $11.75 billion acquisition of US-based Organon & Co. This acquisition is expected to significantly strengthen Sun Pharma's business position, almost doubling its revenue and expanding its geographic reach, particularly in women's health and biosimilars. The transaction, backed by a $12 billion bridge loan and substantial cash reserves, is anticipated to close by March 2027.
Organon & Co stock hits 52-week high at $13.78
Organon & Co's stock has reached a new 52-week high of $13.78, marking a 46.07% increase over the past year, driven by significant developments. These include a global licensing agreement for the hormone-free IUD Miudella, exclusive commercialization rights for biosimilar PYZCHIVA in Canada, and expanded FDA indications for biosimilar TOFIDENCE. The company is also presenting new Phase 3 data for VTAMA cream, showcasing ongoing efforts to expand its product offerings and market presence.
Organon & Co stock hits 52-week high at $13.78 By Investing.com
Organon & Co's stock reached a 52-week high of $13.78, marking a 46.07% increase over the past year due to positive market momentum and investor confidence. This surge follows recent company developments, including a licensing agreement for Miudella, commercialization rights for PYZCHIVA, and expanded FDA indications for TOFIDENCE.
Organon & Co stock hits 52-week high at $13.78 By Investing.com
Organon & Co's stock has reached a new 52-week high of $13.78, marking a 46.07% increase over the past year, driven by investor confidence and recent company developments. These developments include a global licensing agreement for the hormone-free copper IUD Miudella, exclusive commercialization rights for the biosimilar PYZCHIVA in Canada, and expanded FDA approvals for its biosimilar TOFIDENCE. The company is also preparing to present new Phase 3 data for VTAMA cream in atopic dermatitis.
Organon & Co. (OGN) Short Interest & Short Float | Updated Aug 2026 $OGN
As of August 14, 2026, Organon & Co. (OGN) had a short interest of 15.14 million shares, a 9.92% decrease from the prior report, representing 5.86% of its public float. The short interest ratio is 6.1 days to cover. This report details the historical short interest data for OGN, along with comparisons to peers and explanations of key short interest metrics.
Organon earnings up next: Can drugmaker rebound after Q1 miss?
Organon & Co. is set to report second-quarter earnings, with investors keen to see if the women's health drugmaker can recover from a disappointing first quarter. The report comes amidst a pending acquisition by Sun Pharmaceutical, which adds complexity to the company's future outlook. Analysts hold a neutral stance on the stock, citing skepticism about growth prospects despite recent product developments.
Organon earnings up next: Can drugmaker rebound after Q1 miss?
Organon & Co. is set to report second-quarter earnings, with analysts expecting improved sequential performance but a year-over-year decline. The report will be crucial for the women's health drugmaker to demonstrate a rebound after a disappointing first quarter, especially as its pending acquisition by Sun Pharmaceutical adds an element of uncertainty. Investors will be scrutinizing the performance of its core women's health franchise and management commentary on biosimilars and established brands.
Organon & Co stock hits 52-week high at 13.73 USD
Organon & Co (OGN) stock has reached a new 52-week high of $13.73, following an 83% surge over the past six months and 92% year-to-date returns. InvestingPro analysis suggests the stock is still undervalued with a fair value of $20.04, highlighting strong free cash flow and shareholder yield. The company has also expanded its product portfolio with FDA-approved biosimilars and licensing agreements.
how InvestingPro’s Fair Value spotted Organon’s 69% gain potential By Investing.com
InvestingPro's Fair Value analysis successfully identified Organon & Co. (NYSE:OGN) as a significantly undervalued stock in early February 2026, predicting a substantial upside potential when it was trading at $8.00 per share. The analysis proved accurate, as the stock surged 68.75% to $13.50 by late June 2026, driven by factors like acquisition rumors, a cleared audit, and new product approvals. This case highlights how InvestingPro's comprehensive valuation methodology can uncover investment opportunities missed by the broader market.
Organon (OGN): Pentwater Capital discloses 18.1M-share, 6.9% ownership stake
Pentwater Capital Management LP and Matthew Halbower have disclosed a passive ownership stake of 6.9% in Organon & Co., totaling 18,100,000 shares. This is based on 262,609,433 shares outstanding as of June 15, 2026. The shares are held by investment funds advised by Pentwater, with shared voting and dispositive power over the entire stake, and the funds retain the right to receive dividends and sale proceeds.
Kevin Hern sells stocks in Organon & Co. and Versant Media Group
Representative Kevin Hern recently sold shares in Organon & Co. (OGN) and Versant Media Group, Inc. (VSNT) on August 5, 2026, with each transaction valued between $1,001 and $15,000. The sales involved stocks held by the Hern Family Revocable Trust and the Hern Family Foundation. While these transactions offer insight into a Congress member's financial activity, they are personal decisions and do not necessarily reflect broader market trends or Hern's views on the companies.
Quantinno Capital Management LP Sells 98,466 Shares of Organon & Co. $OGN
Quantinno Capital Management LP reduced its stake in Organon & Co. by 27.1% in the first quarter, selling 98,466 shares. Meanwhile, several other institutional investors significantly increased their holdings, contributing to institutions collectively owning 77.43% of the stock. Despite Organon & Co. shares trading near a 12-month high, analysts maintain a "Reduce" rating with a consensus price target below current trading levels.
Sei Investments Co. Has $1.14 Million Holdings in Organon & Co. $OGN
Sei Investments Co. significantly increased its stake in Organon & Co. by 82% in the first quarter, now holding 190,057 shares valued at approximately $1.14 million. Organon's shares have shown strong performance, trading near their 52-week high, and the company recently declared a quarterly dividend. Despite this, analysts maintain a cautious "Reduce" rating with an average target price of $11.40.
Organon & Co To Go Ex-Dividend On August 14th, 2026 With 0.02 USD Dividend Per Share
Organon & Co will go ex-dividend on August 14th, 2026. The company is set to pay a dividend of 0.02 USD per share. This indicates a forthcoming dividend payment for shareholders.
Organon & Co. (OGN) CMO exercises 11,519 RSUs and withholds 4,134 shares for costs
Organon & Co.'s Chief Medical Officer, Juan Camilo Arjona Ferreira, exercised 11,519 restricted stock units (RSUs) on August 11, 2026, converting them into common shares. Concurrently, 4,134 common shares were withheld at $13.62 per share to cover exercise costs or tax liabilities. This transaction reflects the final vesting of these RSUs, which occurred in three equal installments.
Organon & Co. $OGN Shares Purchased by California State Teachers Retirement System
California State Teachers Retirement System significantly increased its stake in Organon & Co. ($OGN) by 34.8% in the first quarter, bringing its total holdings to 327,075 shares valued at approximately $1.96 million. Despite institutional investors collectively owning 77.43% of the company, analyst sentiment remains cautious with a consensus "Reduce" rating and an average price target of $11.40. Organon & Co. recently traded near its 12-month high and announced a quarterly dividend of $0.02 per share.
MIUDELLA’s hormone-free IUD requires provider training before use
Organon has launched the Risk Evaluation and Mitigation Strategy (REMS) Program for its hormone-free copper intrauterine device (IUD), MIUDELLA, ahead of its anticipated commercial availability in late 2026. This program mandates training and certification for healthcare providers, healthcare settings, and eligible specialty pharmacies to ensure proper insertion and safe use of the device. The REMS program aims to mitigate risks associated with improper insertion and was implemented following clinical trials demonstrating MIUDELLA's 99% efficacy over three years.
Sun Pharma's Organon deal set to reshape biosimilars competitive landscape
Sun Pharmaceutical Industries is proceeding with its US$11.75 billion acquisition of Organon, a move poised to significantly impact the biosimilars market and make Sun Pharma one of the world's largest pharmaceutical companies by revenue. This acquisition, expected to close in early 2027, will expand Sun Pharma's global reach, especially in women's health and biosimilars, by leveraging Organon's commercial networks in over 140 countries. The deal highlights a growing trend of consolidation in the biosimilars sector, driven by the need for greater scale and market access.
Organon earnings in focus as Sun Pharma deal looms
Organon & Co. is reporting its second-quarter earnings, with analysts expecting $0.90 per share on $1.57 billion in revenue. Investors will be closely watching for operational improvements and stabilization in the women’s health franchise, especially given the impending $11.75 billion acquisition by Sun Pharmaceutical. The earnings report is critical for assessing the company's standalone performance and its impact on the pending deal.
Organon & Co. (OGN) Stock Forecasts
This article provides a brief overview of Organon & Co. (OGN), a pharmaceutical company focused on women's health, biosimilars, and established brands. It references an Argus research report from August 5, 2026, which includes a summary of the company and its current stock price of $13.60. The article encourages users to upgrade for full access to premium research reports.
Organon & Co. $OGN Shares Sold by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP significantly reduced its stake in Organon & Co. ($OGN) by 3.5% in the first quarter, selling over 118,000 shares while still retaining a substantial holding. Despite this reduction and a consensus "Reduce" rating from analysts with an average price target of $11.40, other institutional investors like Vanguard Group and State Street Corp increased their positions. Organon & Co. announced a quarterly dividend of $0.02 per share, and the company's shares opened near their 52-week high at $13.55.
Organon & Co stock hits 52-week high at 13.61 USD
Organon & Co (OGN) stock has reached a new 52-week high of $13.61, marking a 47.51% increase over the past year and reflecting strong investor confidence. The company also announced several recent developments, including a global licensing agreement for Miudella, exclusive commercialization rights for PYZCHIVA in Canada, and expanded FDA approvals for TOFIDENCE. Upcoming presentations on VTAMA cream data further highlight Organon's active pipeline and market presence.
OGN (NYSE: OGN) details 14,761-share Rule 144 common stock sale plan
Organon & Co. (OGN) has filed a Rule 144 notice for the proposed sale of 14,761 shares of common stock through Morgan Stanley Smith Barney LLC, valued at $200,306.77. The filing also details future restricted stock vesting events, including 2,384 shares on November 7, 2024, 5,245 shares on March 29, 2025, and 7,015 shares on March 31, 2025, among other smaller amounts. This indicates a planned release of shares into the market in accordance with SEC regulations.
Vanguard Portfolio Management (OGN) discloses 15.2M-share, 5.77% Organon & Co stake
Vanguard Portfolio Management LLC and affiliated entities have reported a beneficial ownership of 15,161,710 shares in Organon & Co, constituting a 5.77% stake in the company. Vanguard holds sole voting power over 29,592 shares and sole dispositive power over all 15.16 million shares. This disclosure, filed as an amended SCHEDULE 13G/A, aggregates holdings from various Vanguard funds and managed accounts.
Press Release: Organon Announces Quarterly Dividend
Organon (NYSE: OGN) has announced a quarterly dividend of $0.28 per share of common stock. The dividend is payable on September 12, 2024, to shareholders of record as of the close of business on August 21, 2024.
Organon declares $0.02 quarterly dividend per share
Organon & Co. (NYSE: OGN) has announced a quarterly dividend of $0.02 per share of common stock. This dividend is scheduled to be paid on September 10, 2026, to shareholders recorded by August 14, 2026. Organon is a healthcare company based in Jersey City, New Jersey, focusing on women’s health and general medicines across over 140 markets.
Organon & Co. 2026: Revenue $1.56B, EPS $0.4— 10-Q Summary
Organon & Co. reported its 2026 quarterly results, showing a decline in revenue, net income, and diluted EPS compared to the prior-year quarter. Revenue was $1.56 billion, with a diluted EPS of $0.4. The company is in the process of being acquired by Sun Pharma and is undergoing restructuring.
OGN|Organon & Co|Price:13.550|Chg%:+0.030
Organon & Co (OGN) stock currently trades at $13.545, with its fundamentals described as stable and growth potential high. TradingKey rates its valuation as "fairly valued" within the Pharmaceuticals industry, although it notes the stock is considered overvalued based on its PE ratio. Institutional ownership is very high, but there has been a slight decrease in holdings quarter-over-quarter.
OGN|Organon & Co|Price:13.535|Chg%:+0.015
This article provides a detailed company profile of Organon & Co (OGN), a global healthcare company specializing in women's health, biosimilars, and established medicines. It includes financial data, market performance, executive compensation, and shareholding information. The company's main revenue source is its Women's Health business.
Sun Pharma to acquire US-based Organon in nearly $11.75 billion deal
India's Sun Pharmaceutical Industries announced its largest overseas acquisition to date, an all-cash deal to buy New York-listed Organon & Co for $11.75 billion. This acquisition will expand Sun Pharma's innovative medicines business, strengthen its presence in established brands and generics, and enable its entry into the biosimilars segment, positioning the combined entity among the top 25 global pharmaceutical companies with revenues around $12.4 billion. The deal is expected to close in early 2027, subject to regulatory and shareholder approvals.
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. (NYSE:OGN). The investigation focuses on whether Organon and its officers engaged in corporate wrongdoing, specifically for investors who purchased Organon securities before November 3, 2022, and continue to hold them. The firm encourages affected stockholders to contact them to learn more and potentially assist in the investigation at no cost.
Organon & Co. (1OGN) Q4 2025 Earnings Report - Results, Call & Slides
Organon & Co. reported Q4 2025 earnings, missing both EPS and revenue expectations with actual EPS of €0.55 against consensus €0.64 and actual revenue of €1.32 billion against an expected €1.35 billion. The company provided a neutral outlook, guiding for roughly flat revenue and adjusted EBITDA of approximately $6.2 billion and $1.9 billion respectively for full-year 2026, while highlighting strong biosimilars performance and cost savings efforts. Despite some commercial headwinds and margin deterioration, Organon is focused on balance sheet repair and debt reduction, targeting net leverage below 4.0x by year-end 2026.
Organon & Co. Shareholders Clear Sun Pharma Merger Deal
Organon & Co. shareholders have approved the proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a special virtual meeting. Shareholders also passed a non-binding advisory vote regarding compensation for executive officers in connection with the merger. The final voting results will be reported in an 8-K filing with the SEC.
Organon's VTAMA Skin-Clearance Response Reached 56.3% in Ages 2–6 at Week 8
Organon (NYSE: OGN) announced new data from a post hoc analysis of its Phase 3 ADORING 1 and 2 trials for VTAMA cream, showing early and consistent improvements in atopic dermatitis across pediatric age groups and adults. The cream demonstrated significant skin clearance and disease severity reduction, with 56.3% of 2-6 year olds achieving vIGA-AD response and 70.2% achieving EASI75 at week 8. These results support VTAMA cream as a valuable nonsteroidal treatment option for a wide range of patients.
Sun Pharma Moves Closer To Record $12 Billion Organon Deal After Shareholders Approval
Organon shareholders have approved Sun Pharmaceutical Industries Ltd.'s proposed acquisition of the U.S.-based drugmaker, valued at about $9.4 billion. This will be Sun Pharma's largest-ever acquisition, surpassing its 2014 Ranbaxy deal, and is expected to close by early 2027, subject to regulatory approvals. The acquisition aims to broaden Sun Pharma's global business, expanding its presence in women's health and established medicines, and diversifying its revenue mix.
ORGANON CANADA ANNOUNCES THE APPOINTMENT OF DOMINIC BÉGIN AS PRESIDENT AND MANAGING DIRECTOR
Organon Canada has announced the appointment of Dominic Bégin as its new President and Managing Director. Bégin, a founding member of Organon Canada's leadership team, will focus on expanding the company's presence, driving growth, and increasing patient access to medicines, including biosimilars. He brings over 25 years of pharmaceutical experience and previously led Organon Canada's Biosimilars and Biologics franchise to significant growth.
Organon stock trades steady as women’s health focus meets mixed earnings momentum
Organon stock demonstrates a balance between its specialized women's health portfolio and its recent financial performance. The company, which separated from Merck, reported $6.26 billion in revenue and $586 million in net income for 2023, while managing its debt and maintaining a $0.28 quarterly dividend. Investors are monitoring its strategic focus on women's health products like Nexplanon and biosimilars, alongside its efforts to reduce debt and sustain dividend stability.
[8-K] Organon & Co. Reports Material Event
Organon & Co. has filed an 8-K report providing supplemental disclosures related to its proposed merger with Sun Pharma, which is scheduled for a stockholder vote on July 23, 2026. The disclosures include approximately $700 million in potential synergies, unaudited financial projections through 2030, current share count, and net debt. A lawsuit challenging the merger's disclosures has led Organon to voluntarily supplement its proxy statement without admitting wrongdoing, as the company denies the allegations.
Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Organon (NYSE: OGN) announced it will release its second-quarter 2026 financial results through its Form 10-Q filing with the SEC, along with a Form 8-K disclosing non-GAAP financial measures. Due to its pending acquisition by Sun Pharmaceutical Industries Limited, the company has suspended quarterly earnings calls. Organon anticipates recording approximately $1 million in milestone expenses for the quarter, but notes that these preliminary estimates are subject to finalization.
Samsung Bioepis and Organon Broaden Biosimilar Access in Australia
Samsung Bioepis and Organon have expanded their collaboration in Australia to include an additional biosimilar, deepening their existing partnership. This agreement grants Organon exclusive commercial rights for the new biosimilar in Australia, while Samsung Bioepis retains development, manufacturing, and regulatory responsibilities. The expansion aims to increase access to biosimilars for Australian patients and contribute to the healthcare system's sustainability, building on previous savings of over $1 billion generated by biosimilars through the Pharmaceutical Benefit Scheme.
Organon (OGN) Q1 2026 earnings summary
Organon (OGN) reported Q1 2026 revenue of $1.46 billion, a 4% decrease year-over-year, despite net income rising by 68% to $146 million and diluted EPS reaching $0.55. The company is in the process of being acquired by Sun Pharma for $14.00 per share, with the merger expected to close in early 2027. Due to the pending merger, Organon has not provided any financial guidance for future quarters.
Organon (OGN) Q1 2026 earnings summary
Organon (OGN) reported Q1 2026 revenue of $1.46 billion, a 4% year-over-year decrease, with net income rising 68% to $146 million and diluted EPS at $0.55. The company divested the Jada System for up to $465 million and signed a definitive merger agreement with Sun Pharma for a cash acquisition of $14.00 per share, expected to close in early 2027. No financial guidance was provided due to the pending merger.
